Please login to the form below

Not currently logged in
Email:
Password:

Dr Reddy's

This page shows the latest Dr Reddy's news and features for those working in and with pharma, biotech and healthcare.

Triplet approvals for myeloma boost Celgene in Q2

Triplet approvals for myeloma boost Celgene in Q2

Revlimid gained on the back of its recent approval alongside Takeda’s Velcade (bortezomib) and dexamethasone as a first-line therapy for adults with multiple myeloma who are not eligible for ... Dr Reddy’s that reduce the risk of a generic entering

Latest news

  • Indivior push to diversify boosted by schizophrenia drug approval Indivior push to diversify boosted by schizophrenia drug approval

    The two approvals come as Indivior is fighting a rearguard action to protect Suboxone from a generic developed by Dr Reddy’s Laboratories. ... Reddy’s generic earlier this month.

  • Indivior slumps as patent dispute rises US generic spectre Indivior slumps as patent dispute rises US generic spectre

    Indivior said it plans to appeal the decision, which held that three US patents on Suboxone were valid but that a generic from Indian drugmaker Dr Reddy's Laboratories drug does ... He said that Dr Reddy's has not yet been granted FDA approval for its

  • Fresenius Kabi buys Akorn and Merck's biosimilar businesses Fresenius Kabi buys Akorn and Merck's biosimilar businesses

    Adding in Merck's biosimilars business takes it right back into the biotech sphere. ... Merck kicked off its biosimilar programme in 2012 via an agreement with India's Dr Reddy's Laboratories at a time when the company was facing patent expiries on some

  • Merck confirms sale of biosimilar division Merck confirms sale of biosimilar division

    The German group kicked off its biosimilar programme in 2012 via an agreement with India's Dr Reddy's Laboratories, at a time when the company was facing patent expiries on ... At the time the Dr Reddy's deal was announced the biosimilars market was a

  • Dr Reddy's brings its generics portfolio to France Dr Reddy's brings its generics portfolio to France

    Adbijit Mukherjee, chief operating officer of Dr Reddy's, said: “It is our constant endeavour to enhance the reach of our affordable and difficult-to-produce drugs. ... Our business expansion in Europe is testimony to Dr Reddy's commitment to ensure

More from news
Approximately 3 fully matching, plus 52 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Dr Reddy's has expanded its collaboration with Amgen in India adding three approved products: Xgeva for treating bone metastases, Vectibix in colorectal cancer therapy and Prolia for osteoporosis. ... Upfront $80m plus $830m in milestones [ex S. Korea].

  • Deal Watch June 2016 Deal Watch June 2016

    The three deals with Mayne Pharma, Impax Laboratories and Dr Reddy's, for a combined value of over $1.5bn, cover portfolios of marketed and approved generic drugs, drugs currently pending ... acquisition assets/ return of rights. 586. Teva and Allergan/

  • Deal Watch March 2016 Deal Watch March 2016

    Two deals involved products at a later stage of development: Dr Reddy's licence for Xenoport's phase II product XP23829 for plaque psoriasis, and Ipsen's licence for Exelixis's ... Collaboration – development. $595. Xenoport/ Dr Reddy's. XP-23829 for

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    The top major pharma mergers, acquisitions and collaborations during the month continued pharma's love affair with oncology. ... 151. UCB/ Dr. Reddy's. Business acquisition. Dermatology, respiratory and paediatric products for South Asia.

  • Pharma deals in April 2015 Pharma deals in April 2015

    Dr Reddy's, Menarini and Cipher Pharmaceuticals have acquired or licensed rights to products in South Asia, Asia Pacific (ex-Japan) and North America and Mexico, respectively.  . ... Previously rumoured, Dr Reddy's acquires rights to dermatology,

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • Dr Reddy's makes senior changes as US generics head exits Dr Reddy's makes senior changes as US generics head exits

    UmangVohra will be replaced by Alok Sonig. Dr Reddy's has appointed Alok Sonig to be its new head of North America generics to take over from Umang Vohra (pictured). ... Vohra's replacement at Dr Reddy's is the company's head of India generics Alok Sonig

  • MedImmune appoints Dr Anand Subramony MedImmune appoints Dr Anand Subramony

    While at Novartis Dr Subramony established and headed company's novel delivery technologies and therapeutics group. ... Prior to that he held leadership positions at Dr. Reddy's Laboratories in Bridgewater, New Jersey and Johnson &Johnson/Alza

  • Pegasus recruits corporate services lead Pegasus recruits corporate services lead

    His team's first priority, Mackenzie-Reid added, was to ensure the market understands Pegasus'new proposition. . ... Clients include Bayer, Novo Nordisk, Fittleworth, Dr Reddy's and Holland &Barrett.

  • New global head of HR for Dr Reddy’s New global head of HR for Dr Reddys

    Sripada Chandrasekhar joins from IBM. Hyderabad, India-headquartered Dr Reddy's Laboratories has appointed a former IBM executive president and global head of human resources. ... Chakraborty remains with Dr Reddy's, and has retained all but the HR

  • Dr Reddy’s appoints Umang Vohra to lead US business Dr Reddys appoints Umang Vohra to lead US business

    Will be replaced as chief financial officer by Saumen Chakraborty. Indian generics company Dr Reddy's Laboratories has appointed Umang Vohra as the new head of its North American business. ... He first joined the company in 2002, moving from Pepsico-India

More from appointments
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...

Infographics